08:42 AM EDT, 03/26/2026 (MT Newswires) -- Agilent Technologies ( A ) said Thursday that the US Food and Drug Administration approved PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying esophageal or gastroesophageal junction carcinoma patients who may be eligible for treatment with Merck's ( MRK ) Keytruda.

PD-L1 IHC 22C3 pharmDx, Code SK006 is also indicated to help identify patients with non-small cell lung cancer, esophageal squamous cell carcinoma, cervical cancer, among others, who may benefit from treatment with Keytruda, the company said.

Agilent ( A ) said that the PD-L1 IHC 22C3 pharmDx, Code SK006 was developed in partnership with Merck ( MRK ).

Shares of Agilent ( A ) were 0.5% higher in premarket trading, while Merck ( MRK ) was down 0.4%.